Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
Executive Summary
Sanofi, Lilly and Novo are the targets, but if lawsuit gains traction, it could put entire PBM rebate model under legal scrutiny.
You may also be interested in...
Mylan’s EpiPen Recall: Another Hit On The Auto-Injector
What began as an overseas recall of one lot made by a Pfizer subsidiary is expanding, threatening to besmirch Mylan’s once golden supply-chain quality record. The recall follows pricing controversy around the EpiPen product got the CEO hauled before Congress.
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
Pricing controversy around the product got the CEO hauled before Congress; now what began as an overseas recall of one lot made by a Pfizer subsidiary threatens to besmirch Mylan’s once golden supply chain quality record.
US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others
As US prosecutors investigate Novo Nordisk and other insulin makers for their pricing and contracts with pharmacy benefit managers, plaintiff firms allege the Danish group engaged in collusive agreements and misled investors about its earnings and forecasts.